Unique ID issued by UMIN | UMIN000027372 |
---|---|
Receipt number | R000031365 |
Scientific Title | A verification study of improvements in the immune activation: an open trial |
Date of disclosure of the study information | 2017/05/17 |
Last modified on | 2017/10/10 07:44:34 |
A verification study of improvements in the immune activation: an open trial
A verification study of improvements in the immune activation
A verification study of improvements in the immune activation: an open trial
A verification study of improvements in the immune activation
Japan |
Healthy Japanese adults
Not applicable | Adult |
Others
NO
To verify the effects of the test beverage on immune activation
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
Scoring of immunological vigor
*Assess at 0 and 4 weeks after consuming
Immunity test
T lymphocyte age, T cells, CD4+T cells / CD8+T cells ratio, naive T cells, naive T cells / memory T cells ratio, B cells, NK cells, CD4+T cells, CD8+T cells, CD8+CD28+T cells, memory T cells
*Assess at 0 and 4 weeks after consuming
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
Duration: 4 weeks
Test beverage: Kiseisui
Dose and direction: Drink 30 mL before the dinner
*If you forget to drink the test beverage drink it between after dinner to before going to bed
40 | years-old | <= |
70 | years-old | > |
Male and Female
1. Japanese people who are 40 or more to less than 70 years old with experiencing fatigue
2. Those who are considered as appropriate for the study by the physician
3. Within 2, Priority selection is made in the order of II: warning zone, III: observation zone, and IV: safety zone, in immunological grade at baseline, and V: sufficiently high and I: critical zone are excluded
1. At least one previous medical history or under the treatment of malignant tumor, heart failure or myocardial infarction
2. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases
3. Those who use or take "Foods for Specified Health Uses" and "Foods with Functional Claims" in daily
4. Those who are smokers
5. Currently taking medicines and/or herbal medicines
6. Those who are allergic to medicines, milk, beans, orange, and/or other food products
7. Those who are pregnant, breast-feeding, and plan to become a pregnant
8. Those who had participated another clinical test for three months when you signed the informed consent form for this trial
9. Others considered as inappropriate for the study by the physician
10
1st name | |
Middle name | |
Last name | Kazuo YAMAMOTO |
ORTHOMEDICO Inc.
CEO
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo.
03-3818-0610
kazu@orthomedico.jp
1st name | |
Middle name | |
Last name | Naoko SUZUKI |
ORTHOMEDICO Inc.
R&D Department
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo.
03-3818-0610
nao@orthomedico.jp
ORTHOMEDICO Inc.
UTP Co., Ltd.
Profit organization
Seishin-kai Medical Association Inc, Takara Medical Clinic
NO
医療法人社団 盛心会 タカラクリニック (東京都)
Seishin-kai Medical Association Inc, Takara Medical Clinic (Tokyo)
2017 | Year | 05 | Month | 17 | Day |
Unpublished
Completed
2017 | Year | 05 | Month | 15 | Day |
2017 | Year | 05 | Month | 18 | Day |
2017 | Year | 05 | Month | 17 | Day |
2017 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031365